Advancements in nanoparticle-based therapies for multidrug-resistant candidiasis infections: a comprehensive review.

Candida auris, a rapidly emerging multidrug-resistant fungal pathogen, poses a global health threat, with cases reported in over 47 countries. Conventional detection methods struggle, and the increasing resistance ofC. auristo antifungal agents has limited treatment options. Nanoparticle-based therapies, utilizing materials like silver, carbon, zinc oxide, titanium dioxide, polymer, and gold, show promise in effectively treating cutaneous candidiasis. This review explores recent advancements in nanoparticle-based therapies, emphasizing their potential to revolutionize antifungal therapy, particularly in combatingC. aurisinfections. The discussion delves into mechanisms of action, combinations of nanomaterials, and their application against multidrug-resistant fungal pathogens, offering exciting prospects for improved clinical outcomes and reduced mortality rates. The aim is to inspire further research, ushering in a new era in the fight against multidrug-resistant fungal infections, paving the way for more effective and targeted therapeutic interventions.

Role of Metal-Organic Frameworks (MOFs) in treating and diagnosing microbial infections.

This review article highlights the innovative role of metal-organic frameworks (MOFs) in addressing global healthcare challenges related to microbial infections. MOFs, comprised of metal nodes and organic ligands, offer unique properties that can be applied in the treatment and diagnosis of these infections. Traditional methods, such as antibiotics and conventional diagnostics, face issues such as antibiotic resistance and diagnostic limitations. MOFs, with their highly porous and customizable structure, can encapsulate and deliver therapeutic or diagnostic molecules precisely. Their large surface area and customizable pore structures allow for sensitive detection and selective recognition of microbial pathogens. They also show potential in delivering therapeutic agents to infection sites, enabling controlled release and possible synergistic effects. However, challenges like optimizing synthesis techniques, enhancing stability, and developing targeted delivery systems remain. Regulatory and safety considerations for clinical translation also need to be addressed. This review not only explores the potential of MOFs in treating and diagnosing microbial infections but also emphasizes their unique approach and discusses existing challenges and future directions.

Niosome as an Effective Nanoscale Solution for the Treatment of Microbial Infections.

Numerous disorders go untreated owing to a lack of a suitable drug delivery technology or an appropriate therapeutic moiety, particularly when toxicities and side effects are a major concern. Treatment options for microbiological infections are not fulfilled owing to significant adverse effects or extended therapeutic options. Advanced therapy options, such as active targeting, may be preferable to traditional ways of treating infectious diseases. Niosomes can be defined as microscopic lamellar molecules formed by a mixture of cholesterol, nonionic surfactants (alkyl or dialkyl polyglycerol ethers), and sometimes charge-inducing agents. These molecules comprise both hydrophilic and hydrophobic moieties of varying solubilities. In this review, several pathogenic microbes such as Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Plasmodium, Leishmania, and Candida spp. have been evaluated. Also, the development of a proper niosomal formulation for the required application was discussed. This review also reviews that an optimal formulation is dependent on several aspects, including the choice of nonionic surfactant, fabrication process, and fabrication parameters. Finally, this review will give information on the effectiveness of niosomes in treating acute microbial infections, the mechanism of action of niosomes in combating microbial pathogens, and the advantages of using niosomes over other treatment modalities.